Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates
Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of earnings estimate for the next year.
Trinity Biotech plc (NASDAQ: TRIB) is likely to earn $1.16 per share in the next year ending December, 2015. Trinity Biotech’s trailing-twelve-month operating margin is 18.98%.
Meridian Bioscience (NASDAQ: VIVO) may earn $1.07 per share in the next year ending September, 2015. Meridian Bioscience’s PEG ratio is 2.19.
SurModics (NASDAQ: SRDX) is projected to earn $1.01 per share for the next year ending September, 2015. SurModics’ trailing-twelve-month revenue is $56.16 million.
Neogen (NASDAQ: NEOG) is expected to earn $0.94 per share over the next year ending May, 2015. Neogen’s trailing-twelve-month ROE is 10.59%.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.